Komori
Occurring Fact4881FunPep Company LimitedPharmaceuticals

Notice of completion of participant enrollment in the additional Phase III clinical trial of the functional peptide “SR-0379”

In the additional Phase III clinical trial of the functional peptide “SR-0379” for skin ulcers, enrollment was completed after the number of participants administered the investigational drug reached 143, meeting the target number of participants. Results will be evaluated after treatment and observation are completed, and preliminary results are scheduled to be disclosed in the first half of 2027.

Worth reading
36Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
143
Cases (number of participants administered the investigational drug)
Wording
Conditional
How definitive the wording is.

Notice of completion of participant enrollment in the additional Phase III clinical trial of the functional peptide “SR-0379”

Subject Entity

FunPep Company Limited (the Company)

Target Locations / Products

Functional peptide “SR-0379” / additional Phase III clinical trial (SR0379-JP-SU-02 trial, Trial 02) / skin ulcers

This disclosure11/16/2026
Amount of Impact on Business Performance

No impact on results for the fiscal year ending December 2026 (impact amount: Not disclosed)

Accounting period in which recognized

Fiscal year ending December 2026 (no impact on results)

Impact on Earnings Forecast

No impact on the FunPep Group’s results for the fiscal year ending December 2026

Outlook

Results will be evaluated after all participants have completed the treatment and observation periods. Preliminary results are expected to be disclosed in the first half of 2027 (January to June).

Event that occurred
ItemDetails
Event nameNotice of completion of participant enrollment in the additional Phase III clinical trial of the functional peptide “SR-0379”
Subject EntityFunPep Company Limited (the Company)
Target Locations / ProductsFunctional peptide “SR-0379” / additional Phase III clinical trial (SR0379-JP-SU-02 trial, Trial 02) / skin ulcers
Amount of Impact on Business PerformanceNo impact on results for the fiscal year ending December 2026 (impact amount: Not disclosed)
Accounting period in which recognizedFiscal year ending December 2026 (no impact on results)
Impact on Earnings ForecastNo impact on the FunPep Group’s results for the fiscal year ending December 2026
OutlookResults will be evaluated after all participants have completed the treatment and observation periods. Preliminary results are expected to be disclosed in the first half of 2027 (January to June).
Planned follow-up disclosurePreliminary results are expected to be disclosed in the first half of 2027 (January to June).
Items this document does not state (17)
Date of occurrenceDate recognized / date notice receivedCauseType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the change

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The number of participants administered the investigational drug reached 143, meeting the target number of participants.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of completion of participant enrollment in the additional Phase III clinical trial of the functional peptide “SR-0379” | FunPep Company Limited (4881) timely disclosure | Komori